Benzothiazole PI3 kinase modulators for cancer treatment

Details Benzothiazole PI3 kinase modulators for cancer treatment Benzothiazole PI3 kinase modulators for cancer treatment

2011-04-19

2011-04-19

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C544S333000, C544S405000, C546S281100, C548S143000, C548S161000, C548S346100

Reexamination Certificate

active

07928140

ABSTRACT:
The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula Iwherein each of A1, A2, A3, A4, X, R1and R2are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

REFERENCES:
patent: 3725428 (1973-04-01), Janiak
patent: 2003/0153568 (2003-08-01), Cusack
patent: WO 2004/007491 (2004-01-01), None
patent: WO 2004/010995 (2004-02-01), None
patent: WO 2004/098494 (2004-11-01), None
patent: WO 2005/003127 (2005-01-01), None
patent: WO 2005/009389 (2005-02-01), None
patent: WO 2005/070920 (2005-08-01), None
patent: WO 2006/039718 (2006-04-01), None
patent: WO 2006/040318 (2006-04-01), None
patent: WO 2006/044732 (2006-04-01), None
patent: WO 2006/051270 (2006-05-01), None
patent: WO 2007/016392 (2007-02-01), None
patent: WO 2008/133192 (2007-04-01), None
patent: WO 2007/076092 (2007-07-01), None
patent: WO 2007/095588 (2007-08-01), None
patent: WO 2007/129044 (2007-11-01), None
patent: WO 2007/129052 (2007-11-01), None
patent: WO 2007/134828 (2007-11-01), None
patent: WO 2007/135398 (2007-11-01), None
patent: WO 2008/003856 (2008-01-01), None
patent: WO 2008/012326 (2008-01-01), None
patent: WO 2008/016131 (2008-02-01), None
patent: WO 2008/025821 (2008-03-01), None
patent: WO 2008/037477 (2008-04-01), None
patent: WO 2008/052733 (2008-05-01), None
patent: WO 2008/116129 (2008-09-01), None
patent: WO 2008/138834 (2008-11-01), None
patent: WO 2008/138889 (2008-11-01), None
patent: WO 2008/144463 (2008-11-01), None
patent: WO 2008/144464 (2008-11-01), None
patent: WO 2008/144465 (2008-11-01), None
patent: WO 2008/150827 (2008-12-01), None
patent: WO 2008/152387 (2008-12-01), None
patent: WO 2008/157191 (2008-12-01), None
patent: WO 2009/000832 (2008-12-01), None
patent: WO 2009/010530 (2009-01-01), None
patent: WO 2009/055418 (2009-04-01), None
patent: WO 2009/129211 (2009-10-01), None
patent: WO 2009/133127 (2009-11-01), None
Altland H.W., et al., A Facile Synthesis of 2-Aminothiazolo[5,4-b]- and 2-Aminothiazolo [4,5-c] pyridines, Journal of Heterocyclic Chemistry, Jan. 1, 1977, pp. 129-134, vol. 14, Heterocorporation. Provo, US.
P. Garay et al., Synthese et etude des activites antiparasitaires et molliscicides de derives polycycliques de la pyridine, European Journal Medicinal Chemistry, 1978, pp. 171-175, vol. 13, No. 2.
P. Garay et al., Synthese et etude des activites antiparasitaires et molliscicides de derives polycycliques de la pyridine, European Journal Medicinal Chemistry, 1978, pp. 171-175, vol. 13, No. 2. (English—Translation).
Patil V.H., et al., Synthesis of some sulphanilamido-benzothiazolyl thiazole derivatives as antibacterial agents, Journal of the Indian Chemical Society, Dec. 1, 1979, pp. 1243-1245, vol. 56, No. 12, The Indian Chemical Society, Calcutta. IN.
Patil V.H., et al., Synthesis of 2-arylamino-4- not 2′-(P-Acetamido-Benzenesulphonamido)-6′-Benzothiazolyl 3/4 Thiazoles & 2-Arylamino-4-(2′-Sulphanilamido-6′-Benzothiazolyl)Thiazoles, Indian Journal of Chemistry, Section B: Organic, Incl. Medicinal, Jan. 1, 1979, pp. 519-521, vol. 17B, No. 5, Publications & Informations Directorate, New Delhi, IN.
Cosulich et al., New Thiazole Pyridine Sulfonamides as Orally Bioavailable Highly Potent PI3 Kinase Inhibitors, Cancer and Infection Research Area, AstraZeneca, Alderley Park, Cheshire, UK. Keystone Conference Presentation, New Mexico, Feb. 15-20, 2007.
Camps et al., Blockade of PI3K gamma Suppresses Joint Inflammation and Damage in Mouse Models of Rheumatoid Arthritis, Nature Medicine, Sep. 2005, pp. 936-943, vol. 11, No. 9.
Hayakawa, et al., Synthesis and Biological Evaluation of Imidazo[1,2-alpha]pyridine derivatives as novel PI3 kinase p110alpha Inhibitors, Bioorganic and Medical Chemistry, 2007, pp. 403-412, vol. 15.
Knight, et al., A Pharmacological Map of the PI3-K Family Defines a Role for p110alpha in Insulin Signaling, Cell, May 19, 2006, pp. 733-747, vol. 125.
Knight, et al., Supplemental Data—A Pharmacological Map of the PI3-K Family Defines a Role for p110alpha in Insulin Signaling, Cell, May 19, 2006, pp. 733-747, vol. 125.

Affiliated with

Also associated with

Rating

Benzothiazole PI3 kinase modulators for cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzothiazole PI3 kinase modulators for cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiazole PI3 kinase modulators for cancer treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2628114